Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 3, 2009, Pages 578-585

  Kamikubo, Yuichi ^a   Neels, Jaap G ^a   Degryse, Bernard ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cell migration; Cell migration signalosome; LDL receptor related protein; PAI 1; Vitronectin

Indexed keywords

JANUS KINASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; SIGNAL PEPTIDE; STAT PROTEIN; VITRONECTIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL MIGRATION; CHEMOTAXIS; ENZYME ACTIVITY; ENZYME INHIBITION; HALF LIFE TIME; LATENT INHIBITION; MITOSIS INHIBITION; MOTOR PERFORMANCE; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL MIGRATION ASSAYS; CELL MOVEMENT; CELLS, CULTURED; FEEDBACK, PHYSIOLOGICAL; HUMANS; JANUS KINASES; LDL-RECEPTOR RELATED PROTEINS; MYOCYTES, SMOOTH MUSCLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; RATS; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; VITRONECTIN;

EID: 58149293068     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.07.006     Document Type: Article

References (36)

1. Ashcom J.D., Tiller S.E., Dickerson K., Cravens J.L., Argraves W.S., and Strickland D.K. The human alpha 2-macroglobulin receptor: identification of a 420-kDa cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin. J Cell Biol 110 (1990) 1041-1048
2. Bajou K., Maillard C., Jost M., Lijnen R.H., Gils A., Declerck P., et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23 (2004) 6986-6990
3. Blasi F., and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3 (2002) 932-943
4. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Collen D., et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation, a gene targeting and gene transfer study in mice. Circulation 96 (1997) 3180-3191
5. Czekay R.-P., Aertgeerts K., Curriden S.A., and Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160 (2003) 781-791
6. De Taeye B., Gils A., and Declerck P.J. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. Thromb Haemost 92 (2004) 898-924
7. de Waard V., Arkenbout K., Carmeliet P., Lindner P., and Pannekoek H. Plasminogen activator inhibitor-1 and vitronectin protect against stenosis in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 22 (2002) 1978-1983
8. Degryse B. Is uPAR the centre of a sensing system involved in the regulation of inflammation?. Curr Med Chem Anti-Inflamm Anti-Allergy Agents 2 (2003) 237-259
9. Degryse B., Resnati M., Rabbani S.A., Villa A., Fazioli F., and Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood 94 (1999) 649-662
10. Degryse B., Sier C.F.M., Resnati M., Conese M., and Blasi F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett 505 (2001) 249-254
11. Degryse B., Orlando S., Resnati M., Rabbani S.A., and Blasi F. Urokinase/urokinase receptor and vitronectin/αvβ3 integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20 (2001) 2032-2043
12. Degryse B., Bonaldi T., Scaffidi P., Müller S., Resnati M., Sanvito F., et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induces chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152 (2001) 1197-1206
13. Degryse B., Neels J.G., Czekay R.-P., Aertgeerts K., Kamikubo Y., and Loskutoff D.J. The LDL-receptor-related protein is a motogenic receptor for PAI-1. J Biol Chem 279 (2004) 22595-22604
14. Degryse B., Resnati M., Czekay R.-P., Loskutoff D.J., and Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 280 (2005) 24792-24803
15. Deng G., Curriden S.A., Wang S., Rosenberg S., and Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J Cell Biol 134 (1996) 1563-1571
16. Deng G., Curriden S.A., Hu G., Czekay R.-P., and Loskutoff D.J. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189 (2001) 23-33
17. DeYoung M.B., Tom C., and Dichek D.A. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 104 (2001) 1972-1977
18. Dufourcq P., Louis H., Moreau C., Daret D., Boisseau M.R., Lamazière J.M., et al. Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol 18 (1998) 168-176
19. Kamikubo Y., Okumura Y., and Loskutoff D.J. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J Biol Chem 277 (2002) 27109-27119
20. Kamikubo Y., De Guzman R., Kroon G., Curriden S., Neels J.G., Churchill M.J., et al. Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. Biochemistry 43 (2004) 6519-6534
21. Kjoller L., Kanse S.M., Kirkegaard T., Rodenburg K.W., Ronne E., Goodman S.L., et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232 (1997) 420-429
22. Lawrence D.A., Berkenpas M.B., Palaniappan S., and Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 269 (1994) 15223-15228
23. Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3 (2005) 35-45
24. Minor K.H., and Peterson C.B. Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix. J Biol Chem 277 (2002) 10337-10345
25. Neels J.G., van Den Berg B.M., Lookene A., Olivecrona G., Pannekoek H., and van Zonneveld A.J. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 274 (1999) 31305-31311
26. Okumura Y., Kamikubo Y., Curriden S.A., Wang J., Kiwada T., Futaki S., et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 277 (2002) 9395-9404
27. Palmieri D., Lee J.W., Juliano R.L., and Church F.C. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 277 (2002) 40950-40957
28. Ploplis V., Cornelissen I., Sandoval-Cooper M.J., Weeks L., Noria F.A., and Castellino F.J. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 158 (2001) 107-117
29. Rodenburg K.W., Kjoller L., Petersen H.H., and Andreasen P.A. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Biochem J 329 (1998) 55-63
30. Schvartz I., Seger D., and Shaltiel S. Vitronectin. Int J Biochem Cell Biol 31 (1999) 539-544
31. Seiffert D., and Loskutoff D.J. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 266 (1991) 2824-2830
32. Sid B., Dedieu S., Delorme N., Sartelet H., Rath G.M., Bellon G., et al. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator. Int J Biochem Cell Biol 38 (2006) 1729-1740
33. Sidenius N., and Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated binding to vitronectin. FEBS Lett 470 (2000) 40-46
34. Stahl A., and Mueller B.M. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 71 (1997) 116-122
35. Stefansson S., and Lawrence D.A. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383 (1996) 441-443
36. Zhou A., Huntington J.A., Pannu N.S., Carrell R.W., and Read R.J. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10 (2003) 541-544